BGI 9004
Alternative Names: BGI-9004Latest Information Update: 12 Jun 2023
At a glance
- Originator BridGene Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action TEA domain transcription factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Jun 2023 Pharmacodynamics, pharmacokinetics and safety data from preclinical study in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 18 Apr 2023 Pharmacodynamics and adverse events data from a preclinical trial in Cancer presented at the American Association for Cancer Research Annual Meeting (AACR 2023)
- 17 Apr 2023 Preclinical trials in Cancer in USA (unspecified route)